AI Summary
Researchers at Washington University School of Medicine in St. Louis have received a $10.9 million grant from the National Cancer Institute to develop new therapies for pancreatic cancer. The grant aims to improve outcomes for patients with pancreatic ductal adenocarcinoma, the deadliest form of pancreatic cancer.
Researchers at Washington University School of Medicine in St. Louis have received an NCI grant that will provide about $10.9 million to research programs for the development of new therapies for pancreatic ductal adenocarcinoma, the deadliest form of pancreatic cancer.
Researchers at Washington University School of Medicine in St. Louis have received a prestigious Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support research and clinical trials aimed at improving therapies for pancreatic cancer.
The five-year grant will provide about $10.9 million to research programs for the development of new therapies for pancreatic ductal adenocarcinoma, the deadliest form of pancreatic cancer. Fewer than 10% of patients with this cancer survive longer than five years after diagnosis.
The SPORE is co-led by David G. DeNardo, PhD, a professor of medicine; Ryan C. Fields, MD, the Kim and Tim Eberlein Distinguished Professor and chief of the Section of Surgical Oncology in the Department of Surgery; and William Hawkins, MD, a professor of surgery and chief of the Section of Hepatobiliary-Pancreatic and Gastrointestinal Surgery.
“We are hopeful we can improve the outcomes for patients with pancreatic cancer with key support from this grant,” said principal investigator DeNardo, a research member of Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine. “The new strategies we will investigate are very thoughtful about the immunology and stromal biology of these tumors.”
The funding will support three major research